NEW YORK, NY--(Marketwired - Apr 30, 2014) - Daxor Corporation, (
The President of Daxor, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 and lost more than one third of his blood. He received a single unit of his own blood which had been frozen four and a half years ago. He had never expected he would have to utilize his own blood. The present guidelines at many hospitals permit patients to lose almost half the blood in their body and have it replaced with salt water unless the patient is symptomatic. Unfortunately sometimes the first symptom is a complete collapse of their circulation, which may lead to a massive stroke, heart attack, or even sudden death.
A recent article in the Wall Street Journal discussed the increasing amounts of people who are storing cord blood which is obtained during the birth of a child. The article noted that the chance of needing to utilize one's own cord blood is approximately 1 in 2,700. In contrast, individuals have a better than 50% chance of requiring a blood transfusion at some point in their lives. Utilization of one's own blood is far safer than use of donor blood for many reasons such as no immuno-suppression and no chance of contracting an undetected infection.
Millions of Americans, such as patients utilizing anti-coagulants, are at a significantly increased risk of bleeding. Unfortunately, only a tiny fraction of these patients take the precaution of storing their own blood in the event of unanticipated bleeding. Pregnant women lose significant amounts of blood during childbirth. The New York State Department of Health has issued a notification about the unacceptable death rate during childbirth from excessive bleeding. The utilization of self-storage of frozen blood can reduce these risks. Daxor Corporation has provided these services since 1987.
For additional information about Idant Laboratories please visit our website at www.idant.com.
Contact Information:
Dr. Gary Fischman
212-330-8514
Richard Dunn
Director of Operations
212-330-8502
Rdunn@daxor.com
Diane Meegan
Investor Relations
212-330-8512
Dmeegan@daxor.com